Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL151 in Perennial Allergic Rhinitis
NCT03655210Phase 3Completed
- Sponsor
- Hanlim Pharm
- Start
- Feb 2017
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bepotastine salicylate in perennial allergic rhinitis (PAR), sponsored by Hanlim Pharm. Started Feb 2017; status: completed.
02
Drugs
bepotastine salicylate
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT03655210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03655210.